CA2212846A1 - Prostate-specific membrane antigen and uses thereof - Google Patents
Prostate-specific membrane antigen and uses thereofInfo
- Publication number
- CA2212846A1 CA2212846A1 CA002212846A CA2212846A CA2212846A1 CA 2212846 A1 CA2212846 A1 CA 2212846A1 CA 002212846 A CA002212846 A CA 002212846A CA 2212846 A CA2212846 A CA 2212846A CA 2212846 A1 CA2212846 A1 CA 2212846A1
- Authority
- CA
- Canada
- Prior art keywords
- psm
- prostate
- antigen
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/394,152 US5935818A (en) | 1995-02-24 | 1995-02-24 | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US08/466,381 | 1995-06-02 | ||
US08/470,735 | 1995-06-02 | ||
US08/394,152 | 1995-06-02 | ||
US08/470,735 US7105159B1 (en) | 1992-11-05 | 1995-06-06 | Antibodies to prostate-specific membrane antigen |
US08/466,381 US6953668B1 (en) | 1992-11-05 | 1995-06-06 | Prostate-specific membrane antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2212846A1 true CA2212846A1 (en) | 1996-08-29 |
Family
ID=27410106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002212846A Abandoned CA2212846A1 (en) | 1995-02-24 | 1996-02-23 | Prostate-specific membrane antigen and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US7037647B1 (de) |
EP (2) | EP1754788A3 (de) |
JP (4) | JP2001526522A (de) |
AT (1) | ATE317435T1 (de) |
AU (1) | AU717937B2 (de) |
CA (1) | CA2212846A1 (de) |
DE (1) | DE69635801T2 (de) |
MX (1) | MX9706311A (de) |
WO (1) | WO1996026272A1 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6103237A (en) * | 1993-07-22 | 2000-08-15 | Hybritech Incorporated | Stable variant hK2 polypeptide |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
EP0804593A1 (de) * | 1994-05-10 | 1997-11-05 | Mayo Foundation For Medical Education And Research | Rekombinantes hk2 polypeptid |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
FR2775984B1 (fr) * | 1998-03-11 | 2006-09-15 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
DK0914155T3 (da) * | 1996-03-25 | 2006-06-26 | Medarex Inc | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen |
US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US6054444A (en) * | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
EP0941368A2 (de) * | 1996-11-14 | 1999-09-15 | Mayo Foundation For Medical Education And Research | Verfahren für den nachweis von metastatischem prostatakrebs |
US6479263B1 (en) | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
US6235486B1 (en) | 1997-06-20 | 2001-05-22 | Mayo Foundation For Medical Education & Research | Method for detection of breast cancer |
US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
WO1999043710A1 (en) * | 1998-02-26 | 1999-09-02 | Beckman Coulter, Inc. | Prostate-specific membrane antigens and methods of making and using |
US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
CZ200113A3 (cs) | 1998-07-06 | 2001-08-15 | Guilford Pharmaceuticals Inc. | Inhibitory NAALAdázy využitelné jako léčiva a farmaceutické kompozice, které je obsahují |
WO2000014234A1 (en) * | 1998-09-08 | 2000-03-16 | Urocor, Inc. | Prostate specific promoter and regulation of gene expression |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2000044940A2 (en) * | 1999-01-28 | 2000-08-03 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2000050457A1 (en) * | 1999-02-22 | 2000-08-31 | Beckman Coulter, Inc. | Prostate-specific membrane antigens and methods of making and using |
ATE397065T1 (de) | 1999-03-01 | 2008-06-15 | Commw Scient Ind Res Org | Regulatorische konstrukte, die das intron 3 des prostat-spezifischen membranatigen-gens enthalten |
EP1177207A4 (de) * | 1999-04-09 | 2003-06-04 | Sloan Kettering Inst Cancer | Für das prostataspezifische membran-antigenartige gen kodierende dna und ihre verwendung |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
EP2277542B1 (de) | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modifizierte Antikörper gegen prostata-spezifisches Membranantigen und ihre Verwendungen |
AU2002305767B2 (en) | 2001-09-20 | 2008-04-10 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
AU2002356844C1 (en) | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
GR20020100189A (el) * | 2002-04-17 | 2003-12-22 | Zeincro Ελλας Ανωνυμη Εταιρεια Συμβουλων Φαρμακευτικων Επιχειρησεων | Προφαρμακα αντιγονων ειδικων της προστατικης μεμβρανης |
ATE408712T1 (de) | 2003-01-10 | 2008-10-15 | Millennium Pharm Inc | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
EP1851251A2 (de) | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoklonale antikörper gegen ein prostataspezifisches membranantigen, das in fucosyl-resten fehlt |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
KR101345288B1 (ko) * | 2007-09-21 | 2013-12-27 | 삼성전자주식회사 | 2축 구동 전자기 스캐너 |
JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
DK2326350T3 (da) | 2008-09-08 | 2013-12-16 | Psma Dev Company L L C | Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller |
EP2334812B1 (de) | 2008-09-20 | 2016-12-21 | The Board of Trustees of The Leland Stanford Junior University | Nichtinvasive diagnose von fötaler aneuploidie mittels sequenzieren |
EP2398504B1 (de) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Verfahren und Kits zur Diagnose von Krebs und Vorhersage des therapeutischen Nutzens |
WO2011069019A2 (en) | 2009-12-02 | 2011-06-09 | David Ho | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
KR20180050321A (ko) | 2015-08-07 | 2018-05-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
EP3589295A4 (de) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | Zusammensetzungen und verfahren für car-t-zelltherapie |
AU2019209428A1 (en) | 2018-01-22 | 2020-07-30 | Endocyte, Inc. | Methods of use for CAR T cells |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
DE3432714A1 (de) | 1984-09-06 | 1986-04-24 | Behringwerke Ag, 3550 Marburg | Tumortherapeutikum und verfahren zu seiner herstellung |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
DE69334071T2 (de) | 1992-11-05 | 2007-10-25 | Sloan-Kettering Institute For Cancer Research | Prostata-spezifisches membranantigen |
US5935818A (en) | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
DK0914155T3 (da) | 1996-03-25 | 2006-06-26 | Medarex Inc | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
JP2002515040A (ja) | 1996-06-17 | 2002-05-21 | ギルフォード・ファーマシューティカルズ・インコーポレイテッド | Naaladアーゼ阻害剤を用いる癌治療方法 |
US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
EP1005348A1 (de) | 1996-09-27 | 2000-06-07 | Guilford Pharmaceuticals Inc. | Naaladase zusammensetzungen und verfahren zur behandlung von glutamatabnormalien und der neuronalen aktivität in tieren |
US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
US6121252A (en) | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
CZ200113A3 (cs) | 1998-07-06 | 2001-08-15 | Guilford Pharmaceuticals Inc. | Inhibitory NAALAdázy využitelné jako léčiva a farmaceutické kompozice, které je obsahují |
US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6348464B1 (en) | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
US20020013295A1 (en) | 2000-05-30 | 2002-01-31 | Slusher Barbara S. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
AU2001265111A1 (en) | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
EP1202440B1 (de) | 2000-10-17 | 2006-12-20 | Omron Corporation | Dämpferschaltung und Leistungswandler der diese anwendet |
AU2002245271B2 (en) | 2001-01-17 | 2008-01-31 | Eisai Inc. | Thiol-based NAALADase inhibitors |
WO2002096460A1 (en) | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
-
1996
- 1996-02-23 US US08/894,583 patent/US7037647B1/en not_active Expired - Fee Related
- 1996-02-23 AT AT96908504T patent/ATE317435T1/de not_active IP Right Cessation
- 1996-02-23 CA CA002212846A patent/CA2212846A1/en not_active Abandoned
- 1996-02-23 EP EP06002339A patent/EP1754788A3/de not_active Withdrawn
- 1996-02-23 AU AU51725/96A patent/AU717937B2/en not_active Ceased
- 1996-02-23 EP EP96908504A patent/EP0812356B1/de not_active Expired - Lifetime
- 1996-02-23 DE DE69635801T patent/DE69635801T2/de not_active Expired - Lifetime
- 1996-02-23 JP JP52582196A patent/JP2001526522A/ja not_active Withdrawn
- 1996-02-23 WO PCT/US1996/002424 patent/WO1996026272A1/en active Search and Examination
-
1997
- 1997-08-19 MX MX9706311A patent/MX9706311A/es not_active IP Right Cessation
-
2004
- 2004-09-02 JP JP2004256270A patent/JP2005036008A/ja not_active Withdrawn
- 2004-09-02 JP JP2004256265A patent/JP2005185276A/ja not_active Withdrawn
- 2004-09-02 JP JP2004256273A patent/JP2005052145A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0812356A1 (de) | 1997-12-17 |
WO1996026272A1 (en) | 1996-08-29 |
JP2005052145A (ja) | 2005-03-03 |
JP2005185276A (ja) | 2005-07-14 |
DE69635801T2 (de) | 2006-11-02 |
JP2001526522A (ja) | 2001-12-18 |
EP0812356A4 (de) | 2002-04-03 |
DE69635801D1 (de) | 2006-04-20 |
EP1754788A3 (de) | 2007-04-25 |
US7037647B1 (en) | 2006-05-02 |
ATE317435T1 (de) | 2006-02-15 |
JP2005036008A (ja) | 2005-02-10 |
EP1754788A2 (de) | 2007-02-21 |
MX9706311A (es) | 1998-06-30 |
EP0812356B1 (de) | 2006-02-08 |
AU717937B2 (en) | 2000-04-06 |
AU5172596A (en) | 1996-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU717937B2 (en) | Prostate-specific membrane antigen and uses thereof | |
US5935818A (en) | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof | |
CA2147499C (en) | Prostate-specific membrane antigen | |
US7399461B2 (en) | Prostate-specific membrane antigen and uses thereof | |
USRE43586E1 (en) | Antibodies to prostate-specific membrane antigen | |
US6953668B1 (en) | Prostate-specific membrane antigen | |
US20100303715A1 (en) | Prostate-specific membrane antigen and uses thereof | |
US20070148662A1 (en) | Prostate-specific membrane antigen | |
US6566063B1 (en) | Methods for determining metastatic potential of breast cancer cells by detecting GSEF gene product expression | |
JP2004521602A (ja) | 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法 | |
EP1225224A1 (de) | Dna der scherbelastungsantwort | |
US6361948B1 (en) | Prognostic compositions for prostate cancer and methods of use thereof | |
US7611892B2 (en) | Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
WO2001009319A1 (fr) | Gene exprime specifiquement dans le muscle cardiaque foetal humain | |
WO2001073022A1 (fr) | Gene associe a la glomerulonephrite proliferative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |